Renovaro Biosciences develops advanced cell, gene, and immunotherapy platforms for oncology. It focuses on diagnostics and therapies for cancer treatment, utilizing AI and liquid biopsies.

Renovaro Biosciences

Google Font API

HSTS

Content Delivery Network

reCAPTCHA

Cloudflare CDN

Cloudflare

Google Universal Analytics

reCAPTCHA v2

HSTS IncludeSubdomains PreLoad

Gravity Forms

Health Care Public Companies With Fewer Than 100 Employees

Los Angeles Companies that Exited

Los Angeles Companies With Fewer Than 50 Employees (Top 10K)

Health Care Public Companies With More Than 10 Employees

Renovaro Biosciences, Inc. is a biotechnology company dedicated to the development of advanced allogenic cell and gene therapies to promote stronger immune system responses, potentially leading to long-term or life-long cancer remission in some of the deadliest cancers, as well as the treatment or cure of serious infectious diseases such as HIV and Hepatitis B virus (HBV).

Los Angeles

California

United States

North America

Renovaro

Renovaro, Inc. Announces $10 million in Equity Committed

Renovaro secures $10 million equity with added warrants

Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy

India

Asia

Singapore

Pakistan

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Enochian Biosciences, Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 18, 2024 4:08 AM	6b9504d6
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 18, 2024 4:08 AM	412c8b91
crunchbase trigger	general	Oct 30, 2024 1:02 PM	c4da1ad8
crunchbase profile	general	Oct 31, 2024 7:57 AM	c8a3e9ff
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	0f050ba8
peers	general	Oct 18, 2024 4:08 AM	a5249957
news basic	general	Oct 18, 2024 4:08 AM	24e1e228
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ENOCHIANBIO

Renovaro Biosciences

Last Close

0.70

04/08 19:58

Market Cap

45.38M

Beta: -

Volume Today

87.29K

Avg: -